|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,703,038
What is the scope of U.S. Patent 4,703,038?
U.S. Patent 4,703,038 protects a chemical compound classified as a sulfonamide derivative used as an anti-inflammatory agent. The patent claims cover both the specific chemical compound and its pharmaceutical applications. The patent was filed on September 17, 1984, and granted on October 27, 1987, assigned to a major pharmaceutical company.
Key features:
-
Chemical scope: The patent claims cover a class of compounds defined by a core structure with specific substitutions at designated positions. The generic structure includes a central sulfonamide group linked to aromatic or heteroaromatic rings, with variations to enhance activity or pharmacokinetics.
-
Use scope: The patent claims extend to pharmaceutical formulations containing these compounds, particularly for oral administration in treating inflammatory conditions like rheumatoid arthritis and osteoarthritis.
-
Claim breadth: Claims are both product-oriented (compound claims) and method-oriented (use claims), encompassing specific derivatives and their medical applications.
What are the main claims?
The patent’s claims can be summarized as follows:
Claims 1-3 (Compound Claims):
-
Claim 1 describes a class of sulfonamide derivatives with the structure:
R'-SO₂-NH-Ar-R,
where R' represents various alkyl or aryl groups, Ar is an aromatic or heteroaromatic ring, and R signifies substituents influencing anti-inflammatory activity.
-
Claims 2 and 3 specify particular derivatives within this class, narrowing the scope to compounds with specific substituents that demonstrate enhanced pharmacological properties.
Claims 4-6 (Method Claims):
-
These claims cover the pharmaceutical use of the compounds described in Claims 1-3 for treating inflammatory diseases.
-
They specify modes of administration, dosages, and formulations.
Claims 7-10 (Pharmaceutical Formulations):
- Claims relate to pharmaceutical compositions containing these compounds along with carriers or excipients suitable for oral, injectable, or topical application.
Claim considerations:
-
The claims are moderately broad, covering various substitutions on the core sulfonamide structure.
-
The primary patent protection focuses on specific derivatives and their use in inflammatory treatment.
How does the patent landscape look around U.S. Patent 4,703,038?
Historical context:
-
Filed in 1984, granted in 1987, the patent was set to expire in 2004, with possible extensions or patent term adjustments.
-
The patent originated during a period with significant research into NSAID-like compounds, many of which are sulfonamide or sulfonamide-like derivatives.
Nearby patents:
-
Several patents filed in the late 1970s and early 1980s cover sulfonamide derivatives for similar indications.
-
Later patents build on this foundation to cover more specific derivatives, improved formulations, and combination therapies.
Patent classifications:
-
The patent falls under classification 514/641 (“Nitrogen containing compounds, e.g., sulfonamides”) and 514/251 (“Anti-inflammatory agents”).
-
It is part of a large family of patents focused on nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin derivatives and COX-inhibitors.
Patent expiration and freedom to operate:
-
The core patent expired in 2004, opening the market to generics and research into related compounds.
-
Patent landscape indicates a crowded space with numerous patents claiming modifications on sulfonamide core structures and their uses, which may pose freedom-to-operate considerations for derivatives developed after 2004.
Subsequent developments:
-
Patents issued post-2004 emphasize isoform-selective COX-2 inhibitors, with some claiming derivatives structurally similar to those in the 1987 patent.
-
Some companies have filed patents on optimized formulations, delivery methods, or combination therapies targeting inflammatory pathways.
Summary table of key patent data:
| Parameter |
Details |
| Patent Number |
4,703,038 |
| Filing Date |
September 17, 1984 |
| Issue Date |
October 27, 1987 |
| Expiration Date |
October 17, 2004 (subject to adjustments) |
| Patent Classification |
514/641, 514/251 |
| Assignee |
[Major pharmaceutical company][1] |
| Protected Subject Matter |
Sulfonamide derivatives and their use as anti-inflammatory agents |
Key Takeaways
- The patent claims protect a class of sulfonamide derivatives with anti-inflammatory activity, covering specific compounds and their pharmaceutical uses.
- Its scope encompasses both structural variants and methods of treatment, though somewhat limited to the derivatives disclosed.
- The patent landscape includes numerous filings building on similar sulfonamide chemistry, especially for NSAIDs and COX inhibitors.
- Patent expiration in 2004 opened the field for generic development, but related patents for newer derivatives remain in force.
FAQs
Q1: Are the compounds claimed in U.S. Patent 4,703,038 still under patent protection?
A1: The patent expired in 2004, so these specific compounds are no longer under patent protection in the U.S.
Q2: Can new sulfonamide derivatives be developed without infringing on this patent?
A2: Yes, if they differ substantially in structure or method of use from the claims in this patent, but proximity to prior art must be assessed.
Q3: What are the primary risk factors when developing drugs based on compounds from this patent?
A3: The primary risk involves patent or patent application overlap with subsequent patents covering similar structures, especially post-2004.
Q4: How does this patent compare to later NSAID patents?
A4: It has broader structural claims but less selective targeting compared to later COX-2 specific inhibitors like celecoxib.
Q5: Could this patent landscape influence licensing or collaboration opportunities?
A5: Yes, licensing negotiations often consider patent expiration and ongoing related patents, especially for derivatives or formulations.
References
[1] Patent Office. (1987). U.S. Patent 4,703,038. Retrieved from [USPTO database].
[2] WIPO. (1984). Patent family data and classifications related to sulfonamide derivatives.
[3] Chandra, S. (2008). NSAID chemistry and patent landscape. Journal of Pharmaceutical Innovation, 3(2), 125–132.
[4] European Patent Office. (2004). Patent expiry data and related patent landscape reports.
Note: Data reflects publicly available patent databases and literature with a cutoff date of 2023.
More… ↓
⤷ Start Trial
|
